TRIPLE NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cancers: XB010 trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for any side effects. About 396 adults with…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 26, 2026 02:25 UTC
-
New hope for tough breast cancer: phase 3 trial of ESG401 launches
Disease control Recruiting nowThis study tests a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. About 504 participants will receive either ESG401 or a chemotherapy chosen by their doctor. The goal is …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 02:24 UTC
-
New drug hope for Hard-to-Treat breast cancer?
Disease control Recruiting nowThis study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer who have already tried 1 to 3 other treatments. The goal is to see if the drug can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also monitor …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated May 26, 2026 02:23 UTC
-
New hope for aggressive breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults with inoperable or metastatic disease will receive either AK11…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 26, 2026 02:23 UTC
-
Ultrasound and immune-boosting drugs may help fight aggressive breast cancer
Disease control Recruiting nowThis study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 58 participants will receive on…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
New combo therapy aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThis study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate all signs of triple-negative breast cancer in 30 people with stage II or III disease. Participants receive the combination for about 4 months, then have surgery. The main goal is…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated May 26, 2026 02:19 UTC
-
New drug EXS74539 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:19 UTC
-
New IgE antibody trial targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific marker (folate receptor alpha). The study has two parts: first, finding a safe dose, and then checking how well that dose …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Epsilogen Ltd • Aim: Disease control
Last updated May 26, 2026 02:17 UTC
-
New combo therapy aims to halt advanced breast cancer
Disease control Recruiting nowThis study is for people with advanced triple-negative breast cancer that cannot be removed by surgery. It tests different ways of combining radiation therapy with immunotherapy to see which pattern works best to stop the cancer from growing. About 60 participants will take part,…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 02:16 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated May 26, 2026 02:16 UTC
-
New drug GTAEXS617 enters human trials for tough cancers
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
New pill aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis early-stage study tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer and tumors with a specific gene change (CCNE1). The main goals are to find a safe dose and see how well the drug works. About 361 participants will…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 02:15 UTC
-
Immune cells engineered to fight advanced breast cancer enter human trials
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target specific markers on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have tried other treatment…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 26, 2026 02:13 UTC
-
New 'Smart Bomb' therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a two-part approach for people with advanced solid tumors that cannot be removed by surgery. First, a radioactive tracer helps doctors see the tumor on scans. Then, a therapeutic dose of radiation is given to destroy cancer cells. The goal is to find the safest a…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated May 26, 2026 02:12 UTC
-
Blood test catches hidden breast cancer before scans can see it
Disease control Recruiting nowThis study is for people with a high-risk type of breast cancer (triple-negative) who still have cancer cells left after standard chemotherapy and surgery. Researchers will use a simple blood test to look for tiny bits of cancer DNA (ctDNA) that might signal the cancer is coming …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
New drug JAB-2485 tested in advanced cancers – hope for shrinking tumors
Disease control Recruiting nowThis study tests a new drug called JAB-2485 in adults with advanced solid tumors (like breast or lung cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 102 participants will take the dr…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
Can adding radiation before surgery boost breast cancer treatment?
Disease control Recruiting nowThis study is for people with operable, lymph node-positive triple negative breast cancer. It tests whether adding low or high dose radiation to standard chemo and immunotherapy before surgery can improve outcomes. Participants receive radiation to the breast tumor over 3 days, t…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug PQ203 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called PQ203 in people with advanced solid tumors, including triple-negative breast cancer. The main goals are to check the drug's safety and find the right dose for future studies. About 80 adults whose cancer has not responded to standard…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New cancer pill shows promise in early trial for tough tumors
Disease control Recruiting nowThis early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Could a probiotic boost breast cancer treatment?
Disease control Recruiting nowThis study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery helps more women with early-stage triple-negative breast cancer achieve a complete response. About 192 participants will be randomly assigned to receive either standard therapy a…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors like bladder, breast, lung, or cervical cancer that have not responded to prior treatments. The main goals are to find the safest dose and see if …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for Hard-to-Treat breast cancer: experimental drug MR001 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MR001 in people with advanced triple-negative breast cancer (TNBC) that has worsened after previous treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. About 42 participants will recei…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
Can a second dose of powerful cancer drugs work again?
Disease control Recruiting nowThis study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Could your cells hold the key to a new cancer therapy?
Knowledge-focused Recruiting nowThis study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …
Matched conditions: TRIPLE NEGATIVE BREAST CANCER (TNBC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC